 For Appointments
617-726-7805
Fax
617-724-6919
Office Address
Masschusetts General Hospital Cancer Center
55 Fruit Street, LH 2nd Floor
Boston, MA 02114
Clinical Interests
Genetic Predisposition to Breast Cancer
Laboratory Interests
Haber Lab
Education
MD Degree: Stanford University, Stanford, CA, 1983
PhD Degree: Stanford University, Stanford, CA, 1983
Postdoctoral Training
Residency in Internal Medicine: Massachusetts General Hospital, Boston, MA
Fellowship in Medical Oncology: Dana Farber Cancer Institute, Boston, MA
Hematology, Brigham and Women's Hospital, Boston, MA
Postdoctoral Research, Massachusetts Institute of Technology
Board Certification
Internal Medicine, 1986
Medical Oncology and Hematology, 1989
My Publications
Link to PubMed Database
Publications
Haber DA, Settleman J. Cancer: drivers and passengers. Nature. 2007 Mar 8;446(7132):145-6.
Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007 Mar;7(3):169-81.
Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, Kim JC, Feinberg AP, Gerald WL, Vargas SO, Chin L, Iafrate AJ, Bell DW, Haber DA. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science. 2007 Feb 2;315(5812):642-5.
Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng CX, Brugge JS, Haber DA. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12405-10.
Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, Christensen JG, Settleman J, Haber DA. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2316-21.
| 
